Facebook Instagram X-twitter Linkedin

AOD 9064 (5mg)

Table of Contents

  • Quickstart Highlights

AOD-9064 (5mg) protocols focus on this research peptide derived from a modified fragment of human growth hormone (HGH), studied for its potential role in promoting lipolysis (fat breakdown) without affecting IGF-1 levels or typical growth hormone pathways. It is primarily explored for targeted fat reduction and metabolic support. This guide outlines a subcutaneous administration approach for the 5 mg vial format.

  • Reconstitute: Add 1.0 mL bacteriostatic water → 5 mg/mL concentration
  • Typical daily range: 0.25–0.5 mg per day (subcutaneous)
  • Easy measuring: At 5 mg/mL, 1 unit = 0.01 mL = 50 mcg (0.05 mg) on a U-100 insulin syringe
  • Storage: Lyophilized: store at −20 °C; after reconstitution, refrigerate at 2–8 °C and use within 2–4 weeks
  • Protocol Overview

Concise summary of the subcutaneous regimen.

  • Goal: Support fat metabolism and lipolysis without systemic GH elevation
  • Schedule: Once daily subcutaneous injections
  • Dose Range: 0.25–0.5 mg per day
  • Cycle Length: Commonly used in 4–8 week cycles depending on goals
  • Dosing Protocol

Suggested approach for the 5 mg vial format.

  • Start: 0.25 mg once daily to assess response
  • Target: 0.3–0.5 mg once daily
  • Frequency: Once per day (subcutaneous)
  • Vial Duration: One 5 mg vial typically lasts 10–20 days, depending on dose
  • Timing: Often administered in the morning or pre-exercise for consistency
  • Mechanism of Action

AOD-9064 is a modified peptide fragment related to the C-terminal region of human growth hormone (commonly studied as AOD-9604 analogs). It is believed to act primarily on fat metabolism pathways by stimulating lipolysis and enhancing fatty acid breakdown.

Unlike full growth hormone, this peptide does not appear to significantly impact IGF-1 levels or promote systemic anabolic effects. Instead, it is studied for its localized metabolic activity, particularly in adipose tissue, where it may support fat oxidation and inhibit fat accumulation. Preclinical research suggests potential benefits in body composition regulation without affecting blood glucose or insulin pathways.

  • Potential Benefits & Side Effects

Observations based on preclinical and early research.

Potential Benefits:

  • May support targeted fat loss through enhanced lipolysis
  • Does not significantly affect IGF-1 or systemic GH levels
  • May assist in improving body composition during calorie deficit
  • Non-stimulant metabolic support mechanism

Possible Side Effects:

  • Mild injection-site irritation
  • Occasional headache or fatigue in some users
  • Limited long-term human clinical data available
  • Remains investigational with incomplete safety profile